{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:36:45Z","timestamp":1789774605969,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10637-025-01556-1","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:25:37Z","timestamp":1750829137000},"page":"750-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Understanding the differentiation syndrome in acute promyelocytic leukemia: a comprehensive updated review"],"prefix":"10.1007","volume":"43","author":[{"given":"Nahed","family":"Damaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toufic","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"1556_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1200\/JCO.2010.32.1067","volume":"29","author":"MA Sanz","year":"2011","unstructured":"Sanz MA, Lo-Coco F (2011) Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 29:495\u2013503. https:\/\/doi.org\/10.1200\/JCO.2010.32.1067","journal-title":"J Clin Oncol"},{"key":"1556_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1046\/j.1365-2141.2000.01936.x","volume":"108","author":"E Di Bona","year":"2000","unstructured":"Di Bona E, Avvisati G, Castaman G et al (2000) Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 108:689\u2013695. https:\/\/doi.org\/10.1046\/j.1365-2141.2000.01936.x","journal-title":"Br J Haematol"},{"issue":"2","key":"1556_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto, the German\u2013Austrian Acute Myeloid Leukemia Study Group, and Study Alliance Leukemia (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa1300874","journal-title":"N Engl J Med"},{"key":"1556_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","volume":"117","author":"SR Frankel","year":"1992","unstructured":"Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr (1992) The \u201cretinoic acid syndrome\u201d in acute promyelocytic leukemia. Ann Intern Med 117:292\u2013296. https:\/\/doi.org\/10.7326\/0003-4819-117-4-292","journal-title":"Ann Intern Med"},{"key":"1556_CR5","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1182\/blood-2009-02-204834","volume":"114","author":"M Luesink","year":"2009","unstructured":"Luesink M, Pennings JLA, Wissink WM, Linssen PCM, Muus P, Pfundt R, de Witte TJM, van der Reijden BA, Jansen JH (2009) Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood 114:5512\u20135521. https:\/\/doi.org\/10.1182\/blood-2009-02-204834","journal-title":"Blood"},{"issue":"1","key":"1556_CR6","doi-asserted-by":"publisher","first-page":"e2011059","DOI":"10.4084\/MJHID.2011.059","volume":"3","author":"P Montesinos","year":"2011","unstructured":"Montesinos P, Sanz MA (2011) The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature. Mediterr J Hematol Infect Dis 3(1):e2011059. https:\/\/doi.org\/10.4084\/MJHID.2011.059","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"6","key":"1556_CR7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/ajh.26142","volume":"96","author":"AT Fathi","year":"2021","unstructured":"Fathi AT, Stein EM, DiNardo CD, Levis MJ, Montesinos P, Botton S (2021) Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. Am J Hematol 96(6):735\u2013746. https:\/\/doi.org\/10.1002\/ajh.26142","journal-title":"Am J Hematol"},{"key":"1556_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/sj.leu.2403284","volume":"18","author":"M Ninomiya","year":"2004","unstructured":"Ninomiya M, Kiyoi H, Ito M, Hirose Y, Ito M, Naoe T (2004) Retinoic acid syndrome in NOD\/scid mice induced by injecting an acute promyelocytic leukemia cell line. Leukemia 18:442\u2013448. https:\/\/doi.org\/10.1038\/sj.leu.2403284","journal-title":"Leukemia"},{"key":"1556_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.leukres.2005.01.005","volume":"29","author":"M Shibakura","year":"2005","unstructured":"Shibakura M, Niiya K, Niiya M, Asaumi N, Yoshida C, Nakata Y, Tanimoto M (2005) Induction of CXC and CC chemokines by all-trans retinoic acid in acute promyelocytic leukemia cells. Leuk Res 29:755\u2013759. https:\/\/doi.org\/10.1016\/j.leukres.2005.01.005","journal-title":"Leuk Res"},{"key":"1556_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1046\/j.1365-2141.1999.01671.x","volume":"107","author":"DC Brown","year":"1999","unstructured":"Brown DC, Tsuji H, Larson RS (1999) All-trans retinoic acid regulates adhesion mechanism and transmigration of the acute promyelocytic leukaemia cell line NB-4 under physiologic flow. Br J Haematol 107:86\u201398. https:\/\/doi.org\/10.1046\/j.1365-2141.1999.01671.x","journal-title":"Br J Haematol"},{"key":"1556_CR11","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1182\/blood.V90.7.2747","volume":"90","author":"RS Larson","year":"1997","unstructured":"Larson RS, Brown DC, Sklar LA (1997) Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2. Blood 90:2747\u20132756. https:\/\/doi.org\/10.1182\/blood.V90.7.2747","journal-title":"Blood"},{"key":"1556_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/(SICI)1097-0215(19970106)70:1<72::AID-IJC11>3.0.CO;2-F","volume":"70","author":"G Taraboletti","year":"1997","unstructured":"Taraboletti G, Borsotti P, Chirivi RGS, Vergani V, Falanga A, Barbui T, Giavazzi R, Rambaldi A (1997) Effect of all trans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. Int J Cancer 70:72\u201377. https:\/\/doi.org\/10.1002\/(SICI)1097-0215(19970106)70:1%3c72::AID-IJC11%3e3.0.CO;2-F","journal-title":"Int J Cancer"},{"key":"1556_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1046\/j.1365-2141.1996.4911029.x","volume":"93","author":"M Marchetti","year":"1996","unstructured":"Marchetti M, Falanga A, Giovanelli S, Oldani E, Barbui T (1996) All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4. Br J Haematol 93:360\u2013366. https:\/\/doi.org\/10.1046\/j.1365-2141.1996.4911029.x","journal-title":"Br J Haematol"},{"key":"1556_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41408-021-00584-3","volume":"11","author":"RJ Stubbins","year":"2021","unstructured":"Stubbins RJ, Karsan A (2021) Differentiation therapy for myeloid malignancies: beyond cytotoxicity. Blood Cancer J 11:193. https:\/\/doi.org\/10.1038\/s41408-021-00584-3","journal-title":"Blood Cancer J"},{"issue":"4","key":"1556_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.leukres.2009.09.017","volume":"34","author":"R Jeddi","year":"2010","unstructured":"Jeddi R, Gh\u00e9dira H, Mnif S, Gouider E, Fenaux P, Meddeb B (2010) High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res 34(4):545\u2013547. https:\/\/doi.org\/10.1016\/j.leukres.2009.09.017","journal-title":"Leuk Res"},{"issue":"4","key":"1556_CR16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","volume":"113","author":"P Montesinos","year":"2009","unstructured":"Montesinos P, Bergua JM, Vellenga E, Ray\u00f3n C, Parody R, De La Serna J, Le\u00f3n A, Esteve J, Milone G, Deb\u00e9n G, Rivas C (2009) Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood J Am Soc Hematol 113(4):775\u2013783. https:\/\/doi.org\/10.1182\/blood-2008-07-168617","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"1556_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1186\/s12885-020-07330-1","volume":"20","author":"L Yamamoto De Almeida","year":"2020","unstructured":"Yamamoto De Almeida L, Pereira-Martins DA, Lima ASG, Baggio MS, De Araujo Koury LC, Lange AP, Bassi SC, Scheucher PS, Rego EM (2020) Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome. BMC Cancer 20(1):821. https:\/\/doi.org\/10.1186\/s12885-020-07330-1","journal-title":"BMC Cancer"},{"key":"1556_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.arbres.2019.11.004","volume":"56","author":"LG Saras\u00faa","year":"2019","unstructured":"Saras\u00faa LG, Ventura-D\u00edaz S, Ayala-Carbonero AM, Gamb\u00ed-Pisonero E, de la Cruz AS-T, P\u00e9rez-Lamas L, Mirambeaux-Villanova RM, Chinea-Rodr\u00edguez A (2019) S\u00edndrome de diferenciaci\u00f3n en paciente con leucemia promieloc\u00edtica aguda: Importancia de la TC de t\u00f3rax. Arch Bronconeumol 56:326\u2013327. https:\/\/doi.org\/10.1016\/j.arbres.2019.11.004","journal-title":"Arch Bronconeumol"},{"key":"1556_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/02841859709172077","volume":"38","author":"MU Islam","year":"1997","unstructured":"Islam MU, Burney IA, Khurshid M (1997) Retinoic acid syndrome\u2014radiological features. Acta Radiol 38:340. https:\/\/doi.org\/10.1080\/02841859709172077","journal-title":"Acta Radiol"},{"key":"1556_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2214\/ajr.178.2.1780475","volume":"178","author":"JI Jung","year":"2002","unstructured":"Jung JI, Choi JE, Hahn ST, Min CK, Kim CC, Park SH (2002) Radiologic features of all-trans-retinoic acid syndrome. AJR Am J Roentgenol 178:475\u2013480. https:\/\/doi.org\/10.2214\/ajr.178.2.1780475","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"1556_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","volume":"113","author":"P Montesinos","year":"2009","unstructured":"Montesinos P, Bergua JM, Vellenga E, Ray\u00f3n C, Parody R, De La Serna J, Le\u00f3n A et al (2009) Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 113(4):775\u201383. https:\/\/doi.org\/10.1182\/blood-2008-07-168617","journal-title":"Blood"},{"key":"1556_CR22","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/01.HS9.0000844852.66856.8e","volume":"6","author":"SM Ben","year":"2022","unstructured":"Ben SM, Bchir M, Berred R, Kharrat R, Aissaoui L, Ben AY, Ben NH, Meddeb B (2022) P491: predictive factors of differentiation syndrome in patients with acute promyelocytic leukemia. HemaSphere 6:390\u2013391. https:\/\/doi.org\/10.1097\/01.HS9.0000844852.66856.8e","journal-title":"HemaSphere"},{"issue":"16","key":"1556_CR23","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","volume":"26","author":"KJ Norsworthy","year":"2020","unstructured":"Norsworthy KJ, Mulkey F, Scott EC, Ward AF, Przepiorka D, Charlab R, Dorff SE et al (2020) Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a US Food and Drug Administration systematic analysis. Clin Cancer Res 26(16):4280\u201388. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0834","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1556_CR24","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","volume":"27","author":"F Ravandi","year":"2009","unstructured":"Ravandi F, Estey E, Jones D, Faderl S, O\u2019Brien S, Fiorentino J, Pierce S et al (2009) Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27(4):504\u201310. https:\/\/doi.org\/10.1200\/JCO.2008.18.6130","journal-title":"J Clin Oncol"},{"issue":"9","key":"1556_CR25","first-page":"3015","volume":"94","author":"MA Sanz","year":"1999","unstructured":"Sanz MA, Mart\u00edn G, Ray\u00f3n C, Esteve J, Gonz\u00e1lez M, D\u00edaz-Mediavilla J, Bolufer P et al (1999) A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML\/RARalpha-positive acute promyelocytic leukemia. PETHEMA Group. Blood 94(9):3015\u201321","journal-title":"Blood"},{"issue":"18","key":"1556_CR26","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1182\/blood-2013-10-512640","volume":"123","author":"MA Sanz","year":"2014","unstructured":"Sanz MA, Montesinos P (2014) How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood 123(18):2777\u201382. https:\/\/doi.org\/10.1182\/blood-2013-10-512640","journal-title":"Blood"},{"issue":"2","key":"1556_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/bjh.16151","volume":"187","author":"M Stahl","year":"2019","unstructured":"Stahl M, Tallman MS (2019) Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol 187(2):157\u2013162. https:\/\/doi.org\/10.1111\/bjh.16151","journal-title":"Br J Haematol"},{"issue":"5","key":"1556_CR28","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1182\/blood-2003-03-0802","volume":"103","author":"Y Tabe","year":"2004","unstructured":"Tabe Y, Konopleva M, Munsell MF, Marini FC, Zompetta C, McQueen T, Tsao T et al (2004) PML-RAR\u03b1 is associated with leptin-receptor induction: the role of mesenchymal stem cell\u2013derived adipocytes in APL cell survival. Blood 103(5):1815\u201322. https:\/\/doi.org\/10.1182\/blood-2003-03-0802","journal-title":"Blood"},{"issue":"11","key":"1556_CR29","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1182\/blood.V84.11.3843.bloodjournal84113843","volume":"84","author":"L Vahdat","year":"1994","unstructured":"Vahdat L, Maslak P, Miller WH, Eardley A, Heller G, Scheinberg DA, Warrell RP (1994) Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN\/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84(11):3843\u201349","journal-title":"Blood"},{"key":"1556_CR30","doi-asserted-by":"publisher","first-page":"101370","DOI":"10.1016\/j.tranon.2022.101370","volume":"18","author":"H Yang","year":"2022","unstructured":"Yang H, Zhou S, Lan D, Bin Y, Bao W, Wang M, Huang F, Peng Z (2022) The expression of Slit2 and Robo1 increased during retinoic acid syndrome in acute promyelocytic leukemia and impacted differentiated cell migration. Transl Oncol 18:101370. https:\/\/doi.org\/10.1016\/j.tranon.2022.101370","journal-title":"Transl Oncol"},{"issue":"6","key":"1556_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","volume":"11","author":"M Yilmaz","year":"2021","unstructured":"Yilmaz M, Kantarjian H, Ravandi F (2021) Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J 11(6):123. https:\/\/doi.org\/10.1038\/s41408-021-00514-3","journal-title":"Blood Cancer J"},{"issue":"1","key":"1556_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2141.2009.07600","volume":"145","author":"M Levi","year":"2009","unstructured":"Levi M, Toh CH, Thachil J, Watson HG (2009) Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 145(1):24\u201333. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07600","journal-title":"Br J Haematol"},{"issue":"2","key":"1556_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa1300874","journal-title":"N Engl J Med"},{"issue":"9","key":"1556_CR34","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1182\/blood-2008-08-143537","volume":"113","author":"MA Sanz","year":"2009","unstructured":"Sanz MA et al (2009) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113(9):1875\u20131891. https:\/\/doi.org\/10.1182\/blood-2008-08-143537","journal-title":"Blood"},{"issue":"21","key":"1556_CR35","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1182\/blood-2014-10-551507","volume":"125","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Ehninger G (2015) How I treat hyperleukocytosis in acute myeloid leukemia. Blood 125(21):3246\u20133255. https:\/\/doi.org\/10.1182\/blood-2014-10-551507","journal-title":"Blood"},{"issue":"4","key":"1556_CR36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1001\/jamaoncol.2024.7033","volume":"11","author":"AP Jillella","year":"2025","unstructured":"Jillella AP, Lee SJ, Altman JK et al (2025) Academic community partnership in acute promyelocytic leukemia and early mortality: the ECOG-ACRIN EA9131 trial. JAMA Oncol 11(4):400\u2013407. https:\/\/doi.org\/10.1001\/jamaoncol.2024.7033","journal-title":"JAMA Oncol"},{"issue":"9","key":"1556_CR37","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood.2023010353","volume":"142","author":"Q Wu","year":"2023","unstructured":"Wu Q, Wu D-P, Chen S, Yang X, Zhang J, Xue M, Dou X, Xue S-L, Qiu H, Tang X, Han Y, Fu J, He X (2023) Improved prevention and treatment strategy of differentiation syndrome contribute to reduce early death of patients with acute promyelocytic leukemia. Blood 142(9):1528\u20131537. https:\/\/doi.org\/10.1182\/blood.2023010353","journal-title":"Blood"},{"key":"1556_CR38","unstructured":"Mirabile M, Ursu S, Fazal S (2024) Managing differentiation syndrome associated with treatment for AML. JHOP, 14(1), Symptom Management Overview."}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01556-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01556-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01556-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:40:47Z","timestamp":1757198447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01556-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1556"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01556-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"4 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}